Temporal relationship between use of NSAIDs, including selective COX-2 inhibitors, and cardiovascular risk

Drug Safety

Volumn 29, Issue 7, 2006, Pages 621-632

  Motsko, Stephen P ^a,e   Rascati, Karen L ^a   Busti, Anthony J ^b,c   Wilson, James P ^a   Barner, Jamie C ^a   Lawson, Kenneth A ^a   Worchel, Jason ^d  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e The Degge Group Ltd   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTIDIABETIC AGENT; ANTIRHEUMATIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CELECOXIB; CILOSTAZOL; CORTICOSTEROID DERIVATIVE; CYCLANDELATE; CYCLOOXYGENASE 2 INHIBITOR; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ETODOLAC; HYPERTENSIVE AGENT; HYPOCHOLESTEROLEMIC AGENT; IBUPROFEN; LOOP DIURETIC AGENT; METHOTREXATE; NABUMETONE; NAPROXEN; NITRATE; NONSTEROID ANTIINFLAMMATORY AGENT; PENTOXIFYLLINE; ROFECOXIB; SALSALATE; UNINDEXED DRUG; WARFARIN;

ACUTE HEART INFARCTION; ADULT; AGED; ANGINA PECTORIS; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DATA BASE; DEMOGRAPHY; DIABETES MELLITUS; DOSE RESPONSE; DRUG EFFECT; DRUG FATALITY; DRUG FORMULARY; DRUG SENSITIVITY; FEMALE; HAZARD ASSESSMENT; HEART ATRIUM FIBRILLATION; HEART DEATH; HEART FAILURE; HEART RATE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY FAILURE; LABORATORY TEST; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MORTALITY; MULTIVARIATE ANALYSIS; NEOPLASM; OSTEOARTHRITIS; PERIPHERAL VASCULAR DISEASE; POST HOC ANALYSIS; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PUBLIC HEALTH SERVICE; RESPIRATORY ARREST; RESPIRATORY FAILURE; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; STROKE; SYSTEMIC LUPUS ERYTHEMATOSUS;

AGE FACTORS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARDIOVASCULAR DISEASES; COHORT STUDIES; CYCLOOXYGENASE 2 INHIBITORS; ETODOLAC; FEMALE; HUMANS; IBUPROFEN; LACTONES; MALE; MIDDLE AGED; NAPROXEN; PYRAZOLES; SULFONAMIDES; SULFONES; TIME FACTORS; UNITED STATES; VETERANS;

EID: 33746841773     PISSN: 01145916     EISSN: 01145916     Source Type: Journal    
DOI: 10.2165/00002018-200629070-00007     Document Type: Article

References (43)

1. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000 Nov 23; 343 (21): 1520-8, 2
2. Ray WA, Stein CM, Daugherty JR, et al. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 2002 Oct 5; 360 (9339): 1071-3
3. Juni P, Nartey L, Reichenbach S, et al. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 2004 Dec 4; 364 (9450): 2021-9
4. Solomon DH, Schneeweiss S, Glynn RJ, et al. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 2004 May 4; 109 (17): 2068-73
5. Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 2005 Feb 5; 365 (9458): 475-81
6. Kimmel SE, Berlin JA, Reilly M, et al. Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann Intern Med 2005 Feb 1; 142 (3): 157-64
7. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005 Mar 17; 352 (11): 1092-102
8. Nussmeier NA, Whelton AA, Brown MT, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005 Mar 17; 352 (11): 1081-91
9. Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005 Mar 17; 352 (11): 1071-80
10. Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 2005 Jun 11; 330 (7504): 1366
11. Johnsen SP, Larsson H, Tarone RE, et al. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study. Arch Intern Med 2005 May 9; 165 (9): 978-84
12. Levesque LE, Brophy JM, Zhang B. The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults. Ann Intern Med 2005 Apr 5; 142 (7): 481-9
13. Solomon D, Avorn J, Sturmer T, et al. Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs. Arthritis Rheum 2006; 54 (5):1378-89.
14. Andersohn F, Suissa S, Garbe E. Use of first- and second-generation cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs and risk of acute myocardial infarction. Circulation 2006; 113 (16):1950-7
15. Caldwell B, Aldington S, Weatherall M, et al. Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis. J R Soc Med 2006; 99: 132-40.
16. Mamdani M, Rochon P, Juurlink DN, et al. Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly. Arch Intern Med 2003 Feb 24; 163 (4): 481-6
17. Shaya FT, Blume SW, Blanchette CM, et al. Selective cyclooxygenase-2 inhibition and cardiovascular effects: an observational study of a Medicaid population. Arch Intern Med 2005 Jan 24; 165 (2): 181-6
18. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000 Sep 13; 284 (10): 1247-55
19. Konstam MA, Weir MR, Reicin A, et al. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation 2001 Nov 6; 104 (19): 2280-8
20. Reicin AS, Shapiro D, Sperling RS, et al. Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone). Am J Cardiol 2002 Jan 15; 89 (2): 204-9
21. White WB, Faich G, Borer JS, et al. Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib. Am J Cardiol 2003 Aug 15; 92 (4): 411-8
22. Kasliwal R, Layton D, Harris S, et al. A comparison of reported gastrointestinal and thromboembolic events between rofecoxib and celecoxib using observational data. Drug Saf 2005; 28 (9): 803-16
23. Pfizer. Pfizer statement on new information regarding cardiovascular safety of celebrex [online]. Available from URL: http://www.pfizer.com/are/ investors_release/2004pr/ mn_2004_1217.cfm. Release date: 12-17-2004. [Accessed 2004 Dec 17]
24. Patrono C, Patrignani P, Garcia Rodriguez LA. Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs. J Clin Invest 2001 Jul; 108 (1): 7-13
25. Walter MF, Jacob RF, Day CA, et al. Sulfone COX-2 inhibitors increase susceptibility of human LDL and plasma to oxidative modification: comparison to sulfonamide COX-2 inhibitors and NSAIDs. Atherosclerosis 2004 Dec; 177 (2): 235-43
26. Whelton A, Fort JG, Puma JA, et al. Cyclooxygenase-2 specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am J Ther 2001 Mar; 8 (2): 85-95
27. Carson JL, Ray WA, Strom BL. Medicaid databases. In: Strom BL, editor. Pharmacoepidemiology. 3rd ed. West Sussex, England: John Wiley amp; Sons Ltd, 2000: 307-24
28. VHA Pharmacy Benefits Management Strategic Healthcare Group and the Medical Advisory Panel. Summary of the Criteria for the Non-formulary Use of Cyclooxygenase 2 (COX-2) Inhibitors in High-Risk Veteran Patients. VHA Pharmacy Benefits Management [online]. Available from URL: http://www.vapbm.org/PBM/ criteria.htm [Accessed 2003 Jun 11]
29. Riendeau D, Percival MD, Brideau C, et al. Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J Pharmacol Exp Ther 2001 Feb; 296 (2): 558-66
30. Reker DM, Hamilton B, Duncan P, et al. Stroke: who's counting what? J Rehabil Res Dev 2001 Mar/Apr; 38 (2): 281-289
31. Petersen LA, Wright S, Normand SL, et al. Positive predictive value of the diagnosis of acute myocardial infarction in an administrative database. J Gen Intern Med 1999 Sep; 14 (9): 555-8
32. Kiyota Y, Schneeweiss S, Glynn RJ, et al. Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. Am Heart J 2004 Jul; 148 (1): 99-104
33. Huang W, Hsiao F, Tsai Y, et al. Cardiovascular events associated with long-term use of celecoxib, rofecoxib and meloxicam in Taiwan. Drug Saf 2006; 29 (3): 261-72
34. Harrison-Woolrych M, Herbison P, McLean R, et al. Incidence of thrombotic cardiovascular events in patients taking celecoxib compared with those taking rofecoxib: interim results from the New Zealand Intensive Medicines Monitoring Programme. Drug Saf 2005; 28 (5): 435-42
35. Clark DW, Layton D, Shakir SA. Do some inhibitors of COX-2 increase the risk of thromboembolic events? Linking pharmacology with pharmacoepidemiology. Drug Saf 2004; 27 (7): 427-56
36. Ouellet M, Riendeau D, Percival MD. A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin. Proc Natl Acad Sci U S A 2001 Dec 4; 98 (25): 14583-8
37. Pitt B, Pepine C, Willerson JT. Cyclooxygenase-2 inhibition and cardiovascular events. Circulation 2002 Jul 9; 106 (2): 167-9
38. Bolli R, Shinmura K, Tang XL, et al. Discovery of a new function of cyclooxygenase (COX)-2: COX-2 is a cardioprotective protein that alleviates ischemia/reperfusion injury and mediates the late phase of preconditioning. Cardiovasc Res 2002 Aug 15; 55 (3): 506-19
39. McGeer PL, McGeer EG, Yasojima K. Expression of COX-1 and COX-2 mRNAs in atherosclerotic plaques. Exp Gerontol 2002 Jul; 37 (7): 925-9
40. FitzGerald GA. COX-2 and beyond: approaches to prostaglandin inhibition in human disease. Nat Rev Drug Discov 2003 Nov; 2 (11): 879-90
41. Belton O, Byrne D, Kearney D, et al. Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. Circulation 2000 Aug 22; 102 (8): 840-5
42. Wright SM, Daley J, Fisher ES, et al. Where do elderly veterans obtain care for acute myocardial infarction: department of Veterans Affairs or Medicare? Health Serv Res 1997 Feb; 31 (6): 739-54
43. Carson JL, Ray WA, Strom BL. Medicaid databases. In: Strom BL, editor. Pharmacoepidemiology. 3rd ed. West Sussex, England: John Wiley amp; Sons Ltd, 2000: 307-24